AllayJ.A., SleepS., LongS., et al. (2011). Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum. Gene Ther., 22, 595–604.
2.
BlacklowN.R., HogganM.D., and RoweW.P. (1968). Serologic evidence for human infection with adenovirus-associated viruses. J. Natl. Cancer Inst., 40, 319–327.
3.
DarbyS.C., KanS.W., SpoonerR.J., et al. (2007). Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood, 110, 815–825.
4.
DavidoffA.M., GrayJ.T., NgC.Y., et al. (2005). Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol. Ther., 11, 875–888.
5.
DavidoffA.M., NgC.Y., SleepS., et al. (2004). Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J. Virol. Methods, 121, 209–215.
6.
DonahueR.E., and DunbarC.E. (2001). Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells. Hum. Gene Ther., 12, 607–617.
7.
GaoG.P., AlviraM.R., WangL., et al. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA, 99, 11854–11859.
8.
GrimmD., ZhouS., NakaiH., et al. (2003). Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood, 102, 2412–2419.
9.
HagstromJ.N., CoutoL.B., ScallanC., et al. (2000). Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter. Blood, 95, 2536–2542.
10.
HerzogR.W., HagstromJ.N., KungS.H., et al. (1997). Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA, 94, 5804–5809.
11.
HerzogR.W., YangE.Y., CoutoL.B., et al. (1999). Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med., 5, 56–63.
12.
HirataR.K., and RussellD.W. (2000). Design and packaging of adeno-associated virus gene targeting vectors. J. Virol., 74, 4612–4620.
13.
KayM.A., MannoC.S., RagniM.V., et al. (2000). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet., 24, 257–261.
14.
LozierJ.N., MetzgerM.E., DonahueR.E., et al. (1999). Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood, 94, 3968–3975.
15.
MannoC.S., ChewA.J., HutchisonS., et al. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 101, 2963–2972.
16.
MannoC.S., ArrudaV.R., PierceG.F., et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 12, 342–347.
17.
McCartyD.M., FuH., MonahanP.E., et al. (2003). Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther., 10, 2112–2118.
18.
McIntoshJ., LentingP.J., RosalesC., et al. (2013). Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood, 121, 3335–3344.
19.
MingozziF., MausM.V., HuiD.J., et al. (2007). CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat. Med., 13, 419–422.
20.
NathwaniA.C., HanawaH., VandergriffJ., et al. (2000). Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38- subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV. Gene Ther., 7, 183–195.
21.
NathwaniA.C., DavidoffA., HanawaH., et al. (2001). Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood, 97, 1258–1265.
22.
NathwaniA.C., DavidoffA.M., HanawaH., et al. (2002). Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood, 100, 1662–1669.
23.
NathwaniA.C., GrayJ.T., NgC.Y., et al. (2006). Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 107, 2653–2661.
24.
NathwaniA.C., GrayJ.T., McIntoshJ., et al. (2007). Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood, 109, 1414–1421.
25.
NathwaniA.C., RosalesC., McIntoshJ., et al. (2011a). Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol. Ther., 19, 876–885.
26.
NathwaniA.C., TuddenhamE.G., RangarajanS., et al. (2011b). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 365, 2357–2365.
27.
ParksW.P., BoucherD.W., MelnickJ.L., et al. (1970). Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses. Infect. Immun., 2, 716–722.
28.
RadcliffeP.A., SionC.J., WilkesF.J., et al. (2008). Analysis of factor VIII mediated suppression of lentiviral vector titres. Gene Ther., 15, 289–297.
29.
SarkarR., TetreaultR., GaoG., et al. (2004). Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood, 103, 1253–1260.
30.
ThomasC.E., StormT.A., HuangZ., and KayM.A. (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol., 78, 3110–3122.
31.
WangZ., MaH.I., LiJ., et al. (2003). Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther, 10, 2105–2111.
32.
WardN.J., BuckleyS.M., WaddingtonS.N., et al. (2011). Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood, 117, 798–807.
33.
YangG.S., SchmidtM., YanZ., et al. (2002). Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J. Virol., 76, 7651–7660.
